Anthera Pharmaceuticals Overview
- Founded
-
2004

- Status
-
Public
- Employees
-
21

- Stock Symbol
-
ANTH

- Investments
-
1
Anthera Pharmaceuticals General Information
Description
Anthera Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. The company currently has one Phase 3-ready clinical program and two Phase 2 clinical programs. It was established in 2004.
Contact Information
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
PINX
Primary Office
- 25801 Industrial Boulevard
- Suite B
- Hayward, CA 94545
- United States
+1 (510) 000-0000
Anthera Pharmaceuticals Stock Performance
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
15.2K |
Anthera Pharmaceuticals Financials Summary
In Thousands, USD |
TTM 31-Mar-2018 | FY 2017 31-Dec-2017 | FY 2016 31-Dec-2016 | FY 2015 31-Dec-2015 |
---|---|---|---|---|
EV | 5,610 | 17,109 | (1,648) | 129,260 |
Revenue | 0 | 0 | 145 | 3,185 |
EBITDA | (22,994) | (26,593) | (55,257) | (34,935) |
Net Income | (23,391) | (26,874) | (55,523) | (35,220) |
Total Assets | 8,811 | 3,673 | 23,471 | 48,125 |
Total Debt | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Anthera Pharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Anthera Pharmaceuticals Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
Anthera Pharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Anthera Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing products to tr
Biotechnology
Hayward, CA
21
As of 2017
00000
00000000
00000
Anthera Pharmaceuticals Competitors (50)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Aerie Pharmaceuticals | Formerly VC-backed | Durham, NC | 000 | 00000 | 000000 - 000 | 00000 |
000000 | Formerly VC-backed | San Diego, CA | 00 | 000.00 | 000000&0 | 000.00 |
000000 000000 0000 | Formerly VC-backed | Seattle, WA | 00 | 00000 | 000000000 | 00000 |
000000000 00000000 | Corporation | Basking Ridge, NJ | 00 | 00000 | 000000&0 | 00000 |
0000000 0000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 000000&0 | 00000 |
Anthera Pharmaceuticals Patents
Anthera Pharmaceuticals Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20170369551-A1 | Methods of treating iga nephropathy and henoch-schonlein purpura nephritis using a b-cell activating factor (baff) inhibitor | Abandoned | 24-Jun-2016 | 000000000000 | |
US-20110301202-A1 | Spla2 inhibitor conjugate compounds and methods of use | Abandoned | 04-Jun-2010 | 00000000000 | |
US-20110269786-A1 | Treatment of major adverse cardiac events and acute coronary syndrome in diabetic patients using secretory phospholipase a2 (spla2) inhibitor or spla2 inhibitor combination therapies | Abandoned | 30-Apr-2010 | 0000000000 | |
CA-2749534-A1 | Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia | Abandoned | 08-Jan-2009 | 000000000 | |
US-20100204249-A1 | Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia | Abandoned | 08-Jan-2009 | A61K45/06 | 0 |
Anthera Pharmaceuticals Executive Team (13)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
John Thompson | Chief Executive Officer & Board Member | ||
Charles Olson | Chief Technology Officer | ||
May Liu | Chief Accounting Officer, Accounting & Senior Vice President |
Anthera Pharmaceuticals Board Members (15)
Name | Representing | Role | Since |
---|---|---|---|
Brent Furse | Self | Board Member | 000 0000 |
Brian Mueller | Self | Board Member | 000 0000 |
Christopher Henney Ph.D | Self | Board Member | 000 0000 |
David Thompson | Self | Board Member | 000 0000 |
John Thompson | Anthera Pharmaceuticals | Chief Executive Officer & Board Member | 000 0000 |
Anthera Pharmaceuticals Signals
Anthera Pharmaceuticals Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Anthera Pharmaceuticals Investments (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
000 00000 000 | 14-Jul-2014 | 000000000 | Buildings and Property | 0000 0000 |